Skip to main content
Bioscience Reports logoLink to Bioscience Reports
. 2019 Aug 15;39(8):BSR20190110. doi: 10.1042/BSR20190110

Association between interleukin-21 gene rs6822844 polymorphism and rheumatoid arthritis susceptibility

Kewei Ren 1, Jilei Tang 2, Luming Nong 3,, Nan Shen 4, Xiaolong Li 5,
PMCID: PMC6695501  PMID: 31366568

Abstract

Controversial results concerning the association between a polymorphism rs6822844 in the interleukin (IL) 21 (IL-21) gene and rheumatoid arthritis (RA) have existed. A meta-analysis to confirm above relationships is necessary to be performed immediately. We conducted a search in the PubMed database, covering all papers published up to 20 October 2018. Overall, six case–control studies with 3244 cases and 3431 healthy controls were included. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of this association. Publication bias was assessed with both Egger’s and Begg’s tests. After calculation, we found that IL-21 rs6822844 polymorphism could decrease RA risk in overall genetic models (allelic contrast: OR = 0.77, 95% CI = 0.62–0.97, P=0.024; TG versus GG: OR = 0.68, 95% CI = 0.50–0.92, P=0.013, and dominant genetic model: OR = 0.72, 95% CI = 0.55–0.94, P=0.016). Similarly, stratified analysis by race, source of control, significantly decreased association was found in Asians, Caucasians and hospital-based (HB) control source. Finally, in the subgroup analysis of rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA) status, poorly decreased relationship was detected between IL-21 rs6822844 polymorphism and RF negative and ACPA positive RA risk, respectively. No obvious evidence of publication bias was detected in overall analysis. In summary, our study indicated that IL-21 rs6822844 polymorphism was significantly associated with decreased RA susceptibility.

Keywords: Interleukin-21, polymorphism, rheumatoid arthritis

Introduction

Rheumatoid arthritis (RA) is a systemic, inflammatory autoimmune disorder with numerous manifestations caused due to intricate chain of events [1]. Cells of the leukocyte lineage such as: monocytes-macrophages, neutrophils, mastocytes, and subsets of T and B cells majorly contribute to the pathogenesis of RA by secreting various cytokines and chemokines [2].

Interleukin (IL) 21 (IL-21), a dual role cytokine discovered during the year 2000 shares similar homology with IL-2 family of cytokines (IL-2, IL-4, and IL-15) [3]. IL-21 interacts with γ chain (γc) of IL-21 receptor (IL-21R) expressed in various immune cells of the leukocyte lineage. IL-21 is predominantly secreted by T helper 17 (Th17) follicular T helper (Tfh) and natural killer T (NKT) cells [4].

In recent years, IL-21 has been found to be a key player in RA pathogenesis and progression [5–7]. In RA pathogenesis, IL-21R is highly expressed on CD4+ T-cell subsets, macrophages, dendritic cells, and synovial fibroblasts [8]. These immune cell subtypes recognize the IL-21 in the microenvironment to carry out several intricate chains of events [9]. IL-21 has been implicated to be an important target in RA therapy and several studies have been put forth to substantiate its role through activation of signaling pathways and in promoting inflammatory condition [10,11].

Several single-nucleotide polymorphisms (SNPs) situated in IL2/IL21 region including: rs13151961, rs13119723, rs6840978, and rs6822844 have proven to be significantly associated with many autoimmune disorders, such as RA [12,13]. Of these, the rs6822844 is a relatively common SNP, which locates in the intergenic region between IL21 and IL2 genes and shows the strongest association with RA susceptibility. There have been several studies testing this SNP for association with RA in Caucasian sample sets, with varying levels of supporting evidence (P=2.8 × 10−4 ∼ 0.24 × 10−4) [14–17].

Taking into consideration the extensive role of IL-21 rs6822844 polymorphism in RA, hence, to derive a more precise estimation of the association of rs6822844 polymorphism between IL-21 gene and RA risk, we performed a meta-analysis of all eligible case–control studies [15,16,18–21].

Materials and methods

Identification and eligibility of relevant studies

We conducted searches on the PubMed database, last search updated on 20 October 2018, with the keywords containing ‘IL-21’ or ‘interleukin 21’, ‘polymorphism’ or ‘variant’ and ‘rheumatoid arthritis’, without any restriction on language or publication year. Using these terms, a total of 16 articles were retrieved, of which 6 articles coincided with the inclusion criteria. We also screened references of the retrieved articles and review articles by a hand search.

Inclusion criteria and exclusion criteria

Studies that were included in our analysis had to meet all the following criteria: (i) the study assessed the correlation between RA and IL-21 rs6822844 polymorphism; (ii) case–control studies; (iii) sufficient genotype numbers for cases and controls. Accordingly, the following exclusion criteria were also used: (i) no control population; (ii) no available genotype frequency, and (iii) duplication of the previous publications.

Data extraction

Two of the authors extracted all data independently, complied with the selection criteria. The following items were collected: first author’s last name, year of publication, country of origin, ethnicity, total case/control number, source of control, Hardy–Weinberg equilibrium (HWE) of controls, and genotyping methods.

Statistical analysis

Odds ratio (OR) with 95% confidence interval (CI) was used to measure the strength of the association between IL-21 rs6822844 polymorphism and RA based on the genotype frequencies in cases and controls. Subgroup analysis stratified by ethnicity was performed first. Source of control subgroup analysis was performed on two classifications: population-based (PB) and hospital-based (HB). Classification of RA based on rheumatoid factor (RF) subgroup analysis was performed: RF-positive (+) RA or RF-negative (−) RA; at the same time, the anti-citrullinated protein antibody (ACPA) subgroup was also assessed: ACPA-positive (+) RA or ACPA -negative (−) RA.

The fixed effects model and the random effects model were used to calculate the pooled OR. The statistical significance of the summary OR was determined with the Z-test. Heterogeneity assumption was evaluated with a chi-square-based Q-test among the studies. A P-value of more than 0.10 for the Q-test indicated a lack of heterogeneity among the studies. In case significant heterogeneity was detected, the random effects model (DerSimonian–Laird method) was used, however, the fixed effects model (Mantel–Haenszel method) was chosen [22,23]. For IL-21 rs6822844, we investigated the relationship between genetic variants and RA risk in allelic contrast (C-allele versus T-allele), homozygote comparison (CC versus TT), dominant genetic model (CC+CT versus TT), heterozygote comparison (CT versus TT), and recessive genetic model (CC versus CT+TT). Funnel plot asymmetry was assessed using Begg’s test and publication bias was assessed using Egger’s test [24]. The departure of frequencies of IL-21 gene polymorphism from expectation under HWE was assessed by χ2 test in controls using the Pearson chi-square test, P<0.05 was considered significant [25]. All statistical tests for this meta-analysis were performed with Stata software (version 11.0; StataCorp LP, College Station, TX).

Results

Eligible studies

In total, 16 articles were collected from the PubMed database via a literature search using different combinations of keywords. As shown in Figure 1, ten articles were excluded (other gene polymorphism, other kinds of disease, and some unrelative articles). Finally, six different articles were included in current meta-analysis, including 3244 cases and 3431 controls concerning the IL-21 rs6822844 polymorphism and RA risk. All the RA patients were followed by the selection of individuals who fulfill the American College of Rheumatology (formerly the American Rheumatism Association) 1987 revised criteria for RA [26]. The controls were unrelated healthy, age, and ethnically matched individuals. Characteristics of studies of IL-21 rs6822844 polymorphism are summarized in Tables 1 and 2. Finally, we checked the Minor Allele Frequency (MAF) reported for the five main worldwide populations in the 1000 Genomes Browser: East Asian (EAS), 0.001; European (EUR), 0.1531; African (AFR), 0.0113; American (AMR), 0.0605; and South Asian (SAS), 0.0685 (Figure 2). The MAF in our analysis was 0.1542 and 0.1790 in the case and control groups, respectively, both higher than the results in the EAS from 1000 Genomes Browser database.

Figure 1. A flowchart illustrating the search strategy used to identify association studies for IL-21 rs6822844 polymorphism and RA risk.

Figure 1

Table 1. Study characteristics from published studies on the association between IL-21 rs6822844 polymorphism and RA risk.

Author Year Country Ethnicity Case Control SOC Case Control Genotype
TT TG GG TT TG GG HWE
Daha 2009 Netherlands Caucasian 877 866 HB 116 53 708 126 73 667 <0.01 MALDI-TOF-MS
Maiti 2010 Turkey Asian 354 368 HB 6 32 316 4 65 299 0.824 TaqMan
Louahchi 2016 Algeria Asian 323 323 PB 6 31 286 10 80 233 0.336 TaqMan
Malinowski 2017 Poland Caucasian 422 338 PB 6 103 313 4 79 255 0.438 TaqMan
Teixeira 2009 France Caucasian 434 434 PB 8 99 327 11 110 313 0.719 TaqMan
Hollis-Moffatt 2010 New Zealand Caucasian 834 1102 PB 30 221 583 29 330 743 0.285 TaqMan

Abbreviations: HWE, Hardy–Weinberg equilibrium of control group; MALDI-TOF-MS, polymerase chain reaction-matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; PB, population-based; SOC, source of control.

Table 2. RA characteristics from published studies on the association for IL-21 rs6822844 polymorphism.

Author Year Ethnicity Types Case Control Case Control
TT TG GG TT TG GG
Louahchi 2016 African ACPA− 73 323 9 9 55 10 80 233
Louahchi 2016 African ACPA+ 258 323 6 26 226 10 80 233
Louahchi 2016 African RF− 101 323 1 7 93 10 80 233
Louahchi 2016 African RF+ 222 323 5 23 194 10 80 233
Daha 2009 Caucasian ACPA- 228 866 8 60 160 126 73 667
Daha 2009 Caucasian ACPA+ 327 866 25 52 250 126 73 667
Daha 2009 Caucasian RF− 250 866 20 38 192 126 73 667
Daha 2009 Caucasian RF+ 487 866 55 53 379 126 73 667

Figure 2. T-allele frequencies for the IL-21 gene rs6822844 polymorphism among cases/controls stratified by ethnicity.

Figure 2

Vertical line, T-allele frequency; Horizontal line, ethnicity type.

Meta-analysis

In the overall analysis, significantly decreased association could be observed between RA risk and the variant genotypes of IL-21 rs6822844 in three different genetic models from whole populations: in the allelic contrast (OR = 0.77, 95% CI = 0.62–0.97, Pheterogeneity<0.001, P=0.024, Figure 3), the heterozygote comparison (OR = 0.68, 95% CI = 0.50–0.92, Pheterogeneity<0.001, P=0.013) and the dominant model (OR = 0.72, 95% CI = 0.55–0.94, Pheterogeneity<0.001, P=0.016) (Table 3).

Figure 3. Forest plot of RA risk associated with IL-21 rs6822844 polymorphism (T-allele versus G-allele) in the overall analysis.

Figure 3

The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.

Table 3. Total and stratified subgroup analysis of IL-21 rs6822844 polymorphism and RA risk.

Variables n Case/Control T-allele versus. G-allele TG versus. GG TT versus. GG TT+TG versus. GG TT versus. TG+GG
OR (95% CI) Ph P OR (95% CI) Ph P OR (95% CI) Ph P OR (95% CI) Ph P OR (95% CI) Ph P
Total 6 3244/3431 0.77 (0.62–0.97) <0.001 0.024 0.68 (0.50–0.92) <0.001 0.013 0.92 (0.741.15) 0.487 0.465 0.72 (0.55–0.94) <0.001 0.016 0.96 (0.771.20) 0.542 0.726
Ethnicity
Asian 2 677/691 0.48 (0.37–0.63) 0.115 <0.001 0.38 (0.28–0.53) 0.231 <0.001 0.74 (0.341.62) 0.202 0.456 0.42 (0.31–0.56) 0.148 <0.001 0.87 (0.401.89) 0.243 0.721
Caucasian 4 2567/2740 0.91 (0.821.01) 0.500 0.066 0.86 (0.75–0.99) 0.392 0.035 0.94 (0.751.18) 0.472 0.589 0.88 (0.78–0.99) 0.556 0.041 0.97 (0.771.22) 0.454 0.795
Source of control
HB 2 1231/1234 0.79 (0.68–0.93) 0.126 0.004 0.58 (0.44–0.78) 0.197 <0.001 0.89 (0.681.16) 0.459 0.378 0.67 (0.441.01) 0.083 0.059 0.92 (0.701.20) 0.398 0.528
PB 4 2013/2197 0.78 (0.551.10) <0.001 0.160 0.73 (0.491.08) <0.001 0.117 1.00 (0.681.48) 0.304 0.996 0.74 (0.501.10) <0.001 0.133 1.06 (0.721.57) 0.401 0.761
RF status
RF+ 2 709/1189 0.63 (0.321.24) 0.004 0.181 0.67 (0.192.43) <0.001 0.544 0.75 (0.541.04) 0.673 0.085 0.61 (0.241.53) 0.001 0.292 0.75 (0.541.03) 0.950 0.074
RF− 2 351/1189 0.47 (0.151.46) 0.003 0.194 0.65 (0.085.44) <0.001 0.689 0.52 (0.32–0.84) 0.466 0.008 0.49 (0.112.22) <0.001 0.357 0.49 (0.31–0.80) 0.651 0.004
ACPA status
ACPA+ 2 585/1189 0.60 (0.331.09) 0.010 0.096 0.80 (0.154.43) <0.001 0.801 0.54 (0.36–0.82) 0.786 0.004 0.62 (0.231.72) <0.001 0.362 0.52 (0.34–0.78) 0.454 0.002
ACPA− 2 301/1189 0.94 (0.751.20) 0.196 0.635 1.31 (0.189.33) <0.001 0.786 0.99 (0.0714.35) <0.001 0.993 1.25 (0.941.66) 0.128 0.121 0.96 (0.0520.27) <0.001 0.977

Abbreviations: Ph, value of Q-test for heterogeneity test; P, Z-test for the statistical significance of the OR.

In the subgroup analysis by ethnicity, there had been decreased relationships between RA risk and IL-21 rs6822844 polymorphism in both Asians (T-allele versus G-allele: OR = 0.48, 95% CI = 0.37–0.63, Pheterogeneity=0.115, P<0.001; TG versus GG: OR = 0.38, 95% CI = 0.28–0.53, Pheterogeneity=0.231, P<0.001 and TT+TG versus GG: OR = 0.42, 95% CI = 0.31–0.56, Pheterogeneity=0.148, P<0.001, Figure 4) and Caucasians (TG versus GG: OR = 0.86, 95% CI = 0.75–0.99, Pheterogeneity=0.392, P=0.035 and TT+TG versus GG: OR = 0.88, 95% CI = 0.78–0.99, Pheterogeneity=0.556, P=0.041, Figure 4 and Table 3). Similar results were also detected in HB subgroup (for example: TG versus GG: OR = 0.58, 95% CI = 0.44–0.78, Pheterogeneity=0.197, P<0.001, Figure 5 and Table 3).

Figure 4. Forest plot of RA risk associated with IL-21 rs6822844 polymorphism (TT+TG versus GG) in the ethnicity subgroup.

Figure 4

The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.

Figure 5. Forest plot of RA risk associated with IL-21 rs6822844 polymorphism (TG versus GG) in the source of control.

Figure 5

The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.

In the stratified analysis by RF status, pooled associations were found between RF RA risk and IL-21 rs6822844 polymorphism in the homozygote comparison (OR = 0.52, 95% CI = 0.32–0.84, Pheterogeneity=0.466, P=0.008, Figure 6) and the recessive genetic model (OR = 0.49, 95% CI = 0.31–0.80, Pheterogeneity=0.651, P=0.004) (Table 2).

Figure 6. Forest plot of RA risk associated with IL-21 rs6822844 polymorphism (TT versus GG) in the autoantibody subgroup (RF and ACPA status).

Figure 6

The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.

In the stratified analysis by ACPA status, pooled associations were found between ACPA+ RA risk and IL-21 rs6822844 polymorphism in the homozygote comparison (OR = 0.54, 95% CI = 0.36–0.82, Pheterogeneity=0.786, P=0.004, Figure 6) and the recessive genetic model (OR = 0.52, 95% CI = 0.34–0.78, Pheterogeneity=0.454, P=0.002) (Table 2).

Sensitivity analysis and publication bias

The Begg’s funnel plot and Egger’s test were performed to assess publication bias. The results did not suggest any evidence of publication bias (for example: T-allele versus G-allele, t = −1.6, P=0.184 for Egger’s test; z = 1.13, P=0.26 for Begg’s test) (Figures 7 and 8, and Table 4). Sensitivity analysis was performed to assess the influence of each individual study on the pooled OR by sequential removal of individual studies. The results suggested that no individual study significantly affected the overall OR dominantly (for example: T-allele versus G-allele, Figure 9).

Figure 7. Begg’s funnel plot for publication bias test (T-allele versus G-allele).

Figure 7

Figure 8. Egger’s publication bias plot (T-allele versus G-allele).

Figure 8

Table 4. Publication bias tests (Begg’s funnel plot and Egger’s test for publication bias test) for IL-21 rs6822844 polymorphism.

Egger’s test Begg’s test
Genetic type Coefficient Standard error t P-value 95% CI of intercept z P-value
T-allele vs. G-allele −3.837 2.394 −1.6 0.184 (−10.485, 2.810) 1.13 0.26
TG vs. GG −3.972 2.067 −1.92 0.127 (−9.712, 1.768) 1.88 0.06
TT vs. GG −0.452 0.564 −0.8 0.467 (−2.020, 1.114) 0.38 0.707
TT+TG vs. GG −4.213 2.275 −1.85 0.138 (−10.531, 2.104) 1.13 0.26
TT vs. TG+GG −0.453 0.565 −0.8 0.467 (−2.022, 1.115) 0.75 0.452

Figure 9. Sensitivity analysis between IL-21 rs6822844 polymorphism and RA risk (T-allele versus G-allele).

Figure 9

Network of gene interaction of IL-21 gene

The network of gene–gene interaction for IL-21 gene was utilized through String online server (http://string-db.org/) (Figure 10) [27].

Figure 10. Human IL-21 interactions network with other genes obtained from String server.

Figure 10

At least ten genes have been indicated to correlate with IL-21 gene. Abbreviations: IFNGR1, interferon γ receptor 1; IL2RA, IL 2 receptor, α; IL2RB, IL 2 receptor, β; IL2RG, IL 2 receptor, γ; IL4R, IL 4 receptor; IL6R, IL 6 receptor; IL7R, IL 7 receptor; IL12RB1, IL 12 receptor, β 1; IL21R, IL 21 receptor; IL23R, IL 23 receptor.

Discussion

RA is a systemic autoimmune disease characterized by chronic persistent synovial joint inflammation resulting in bony erosion, cartilage loss, and often systemic disorders, such as subcutaneous rheumatoid nodules, secondary Sjogren’s syndrome, interstitial lung disease, and systemic vasculitis [28,29]. RA is considered as a complex condition in which a combination of risk alleles from different susceptibility genes predisposes to the development of the disease [30].

Among the different polymorphisms located in the IL2-IL21 region at 4q27, the rs6822844 G/T polymorphism was found to be the most significantly associated with autoimmune disease susceptibility, including RA [12,13]. To the best of our knowledge, rs6822844 is in a noncoding polymorphism located between IL21 (upstream) and IL2 (downstream) with no molecular function identified. However, this polymorphism may play a role in autoimmunity by modulating the gene expression of these two genes or by being in linkage disequilibrium with a causative mutation. Interestingly, the neighboring sequences between up- and downstream for rs6822844 show strong homology with mature microRNA [31,32]. MicroRNAs are post-transcriptional regulators that bind to complementary sequences in the 3′ UTR of target mRNAs, usually resulting in gene silencing inhibiting their translation [33]. The major allele G of the IL2-IL21 rs6822844 polymorphism is conserved in all microRNA precursor hairpin structures. Therefore, it is possible that the mutation might abolish microRNA production, altering the expression of the genes regulated by this microRNA [34].

To indicate the relationship between IL-21 rs6822844 polymorphism and RA risk, to the best of our knowledge, this was the first-time analysis to combine all the publications to evaluate above association. We performed a meta-analysis involving 3244 RA cases and 3431 controls. In overall analysis, decreased relationship was observed between rs6822844 T-allele and RA risk. Furthermore, in the stratified analysis by ethnicity, we found that individuals who carried T-allele or TG genotype had decreased risk of RA both in Asians and Caucasians. Finally, the rs6822844 polymorphism can decrease risk for ACPA+ or RF RA. This indicated IL-21 rs6822844 T-allele was a protective factor for RA susceptibility.

In addition, we used the online analysis system String to predict potential and functional partners (Figure 10). Finally, ten genes were predicted. The highest score of association was IL-21R (Score = 0.996), however, IL-6R had the lowest scores (Score = 0.833). Tan et al. [35] employed RNA sequencing technology to explore the differentially expressed genes (DEGs) of RA patients compared with healthy volunteers. Combined DEGs and bioinformatics analysis indicated that the cytokine imbalance relevant to key molecules: extracellular signal-regulated kinase 1/2, p38 mitogen-activated protein kinase, tumor necrosis factor, colony-stimulating factor 3, IL-6 and interferon gene (IFNG) were responsible for the common comprehensive mechanism of RA [35]. van Steenbergen et al. [36] reported that IL2RA-rs2104286 and soluble IL2Rα-level were associated with RA-persistence, which was known to act as a protective factor against multiple sclerosis, diabetes mellitus, and RA. Li et al. [37] indicated the −590 site and −174 site polymorphisms in the promoter of IL-4 and IL-6, respectively, may be associated with increased risk of RA and could be used as genetic markers for assessing the susceptibility and severity of RA. O’Doherty et al. [38] suggested that TT genotype in IL-7 rs6897932 polymorphism was significantly associated with RA risk. Gomes da Silva et al. [39] suggested that the variants +2199 A/C IL-23R could contribute to RA development. Paradowska-Gorycka et al. [40] indicated that IL-12p40 + 1188A/C polymorphism and IL-12p70 protein levels may be associated with RA. Above information predicted IL family genes, such as IL2A, IL4, IL-6, IL-7, IL-23R, IL-12 and IFNG may influence IL-21 and regulate the RA development, which maybe become intervention and treatment target genes in the future. Besides, Do et al. [41] reported that IL-21 was dispensable for γδ T-cell IL-17A expression in lymph nodes, while Moser et al. [42] indicated that IL-21R signaling suppressed the IL-17A-producing γδ T-cell response in lung after influenza A virus infection. In addition, Huang et al. [43] suggested IL-21/IL-21R may act as a potent inhibitor of IL-17A-producing γδ T cells, controlling neutrophil-dependent inflammatory responses mediated by IL-17A-producing γδ T cells. From above we can see, IL-21 is a significant regulator for IL-17A.

Some limitations in our meta-analysis should be considered. Beginning, the number of published studies included in our meta-analysis remains not sufficiently large for a comprehensive analysis. Second, the interactions between gene–gene, gene–environment, and even different polymorphic loci of the same gene may modulate RA risk. Third, our meta-analysis was based on unadjusted estimates, while a more precise analysis should be conducted if individual data were available, which would allow for the adjustment by other covariates including age, sex, family history, environmental factors, disease stage, and lifestyle.

In summary, our present analysis showed the evidence that IL-21 rs6822844 polymorphism was associated with significantly decreased RA risk not only in Asian but also in Caucasian populations and may be considered as a biomarker in the detection of susceptibility for RA. Therefore, further well-designed large studies, particularly referring to gene–gene and gene–environment interactions are warranted.

Abbreviations

ACPA

anti-citrullinated protein antibody

CI

confidence interval

DEG

differentially expressed gene

EAS

East Asian

HB

hospital-based

IFNG

interferon gene

IL

interleukin

IL-21R

IL-21 receptor

MAF

minor allele frequency

OR

odds ratio

RA

rheumatoid arthritis

RF

rheumatoid factor

SNP

single-nucleotide polymorphism

Author Contribution

K.R. conceived the study. J.T. searched the databases and extracted the data. L.N. analyzed the data. N.S. wrote the draft of the paper. L.N. reviewed the manuscript. X.L. analyzed the data.

Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

Funding

This work was supported by the National Natural and Science Foundation [grant number 81501874]; the Jiangsu Province Health and Family Planning Commission Foundation [grant numbers Q201511, QNRC2016139]; the Wuxi Health and Family Planning Commission Foundation [grant number J201811 (to K.R.)]; the Project of Invigorating Health Care through Science, Technology and Education (Jiangsu Provincial Medical Youth Talent), Changzhou High-level Medical Talents Training Project [grant number 2016CZBJ029]; the Jiangsu Planned Projects for Postdoctoral Research Funds [grant number 1701001A]; and the Changzhou International Scientific and Technology Cooperation Project [grant number CZ20170021 (to L.N.)].

References

  • 1.Trouw L.A., Pickering M.C. and Blom A.M. (2017) The complement system as a potential therapeutic target in rheumatic disease. Nat. Rev. Rheumatol. 13, 538–547 10.1038/nrrheum.2017.125 [DOI] [PubMed] [Google Scholar]
  • 2.Shikhagaie M.M., Germar K., Bal S.M., Ros X.R. and Spits H. (2017) Innate lymphoid cells in autoimmunity: emerging regulators in rheumatic diseases. Nat. Rev. Rheumatol. 13, 164–173 10.1038/nrrheum.2016.218 [DOI] [PubMed] [Google Scholar]
  • 3.Leonard W.J. and Spolski R. (2005) Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat. Rev. Immunol. 5, 688–698 10.1038/nri1688 [DOI] [PubMed] [Google Scholar]
  • 4.Varricchi G., Harker J., Borriello F., Marone G., Durham S.R. and Shamji M.H. (2016) T follicular helper (Tfh) cells in normal immune responses and in allergic disorders. Allergy 71, 1086–1094 10.1111/all.12878 [DOI] [PubMed] [Google Scholar]
  • 5.Kwok S.K., Cho M.L., Park M.K., Oh H.J., Park J.S., Her Y.M.. et al. (2012) Interleukin-21 promotes osteoclastogenesis in humans with rheumatoid arthritis and in mice with collagen-induced arthritis. Arthritis Rheum. 64, 740–751 10.1002/art.33390 [DOI] [PubMed] [Google Scholar]
  • 6.Xing R., Jin Y., Sun L., Yang L., Li C., Li Z.. et al. (2016) Interleukin-21 induces migration and invasion of fibroblast-like synoviocytes from patients with rheumatoid arthritis. Clin. Exp. Immunol. 184, 147–158 10.1111/cei.12751 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Xing R., Yang L., Jin Y., Sun L., Li C., Li Z.. et al. (2016) Interleukin-21 induces proliferation and proinflammatory cytokine profile of fibroblast-like synoviocytes of patients with rheumatoid arthritis. Scand. J. Immunol. 83, 64–71 10.1111/sji.12396 [DOI] [PubMed] [Google Scholar]
  • 8.Lubberts E. (2010) Th17 cytokines and arthritis. Semin. Immunopathol. 32, 43–53 10.1007/s00281-009-0189-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Andersson K.M., Cavallini N.F., Hu D., Brisslert M., Cialic R., Valadi H.. et al. (2015) Pathogenic transdifferentiation of Th17 cells contribute to perpetuation of rheumatoid arthritis during anti-TNF treatment. Mol. Med. 21, 536–543 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Jang E., Cho S.H., Park H., Paik D.J., Kim J.M. and Youn J. (2009) A positive feedback loop of IL-21 signaling provoked by homeostatic CD4+CD25- T cell expansion is essential for the development of arthritis in autoimmune K/BxN mice. J. Immunol. (Baltimore) 182, 4649–4656 10.4049/jimmunol.0804350 [DOI] [PubMed] [Google Scholar]
  • 11.Young D.A., Hegen M., Ma H.L., Whitters M.J., Albert L.M., Lowe L.. et al. (2007) Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum. 56, 1152–1163 10.1002/art.22452 [DOI] [PubMed] [Google Scholar]
  • 12.Festen E.A., Goyette P., Scott R., Annese V., Zhernakova A., Lian J.. et al. (2009) Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis. Gut 58, 799–804 10.1136/gut.2008.166918 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.van Heel D.A., Franke L., Hunt K.A., Gwilliam R., Zhernakova A., Inouye M.. et al. (2007) A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat. Genet. 39, 827–829 10.1038/ng2058 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Barton A., Eyre S., Ke X., Hinks A., Bowes J., Flynn E.. et al. (2009) Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes. Hum. Mol. Genet. 18, 2518–2522 10.1093/hmg/ddp177 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Daha N.A., Kurreeman F.A., Marques R.B., Stoeken-Rijsbergen G., Verduijn W., Huizinga T.W.. et al. (2009) Confirmation of STAT4, IL2/IL21, and CTLA4 polymorphisms in rheumatoid arthritis. Arthritis Rheum. 60, 1255–1260 10.1002/art.24503 [DOI] [PubMed] [Google Scholar]
  • 16.Teixeira V.H., Pierlot C., Migliorini P., Balsa A., Westhovens R., Barrera P.. et al. (2009) Testing for the association of the KIAA1109/Tenr/IL2/IL21 gene region with rheumatoid arthritis in a European family-based study. Arthritis Res. Ther. 11, R45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Zhernakova A., Alizadeh B.Z., Bevova M., van Leeuwen M.A., Coenen M.J., Franke B.. et al. (2007) Novel association in chromosome 4q27 region with rheumatoid arthritis and confirmation of type 1 diabetes point to a general risk locus for autoimmune diseases. Am. J. Hum. Genet. 81, 1284–1288 10.1086/522037 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Hollis-Moffatt J.E., Chen-Xu M., Topless R., Dalbeth N., Gow P.J., Harrison A.A.. et al. (2010) Only one independent genetic association with rheumatoid arthritis within the KIAA1109-TENR-IL2-IL21 locus in Caucasian sample sets: confirmation of association of rs6822844 with rheumatoid arthritis at a genome-wide level of significance. Arthritis Res. Ther. 12, R116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Louahchi S., Allam I., Raaf N., Berkani L., Boucharef A., Abdessemed A.. et al. (2016) Association of rs6822844 within the KIAA1109/TENR/IL2/IL21 locus with rheumatoid arthritis in the Algerian population. HLA 87, 160–164 10.1111/tan.12757 [DOI] [PubMed] [Google Scholar]
  • 20.Maiti A.K., Kim-Howard X., Viswanathan P., Guillen L., Rojas-Villarraga A., Deshmukh H.. et al. (2010) Confirmation of an association between rs6822844 at the IL2-IL21 region and multiple autoimmune diseases: evidence of a general susceptibility locus. Arthritis Rheum. 62, 323–329 10.1002/art.27222 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Malinowski D., Paradowska-Gorycka A., Safranow K. and Pawlik A. (2017) Interleukin-21 gene polymorphism rs2221903 is associated with disease activity in patients with rheumatoid arthritis. Arch. Med. Sci. 13, 1142–1147 10.5114/aoms.2017.68945 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.DerSimonian R. and Laird N. (1986) Meta-analysis in clinical trials. Control. Clin. Trials 7, 177–188 10.1016/0197-2456(86)90046-2 [DOI] [PubMed] [Google Scholar]
  • 23.Mantel N. and Haenszel W. (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 22, 719–748 [PubMed] [Google Scholar]
  • 24.Hayashino Y., Noguchi Y. and Fukui T. (2005) Systematic evaluation and comparison of statistical tests for publication bias. J. Epidemiol. 15, 235–243 10.2188/jea.15.235 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Napolioni V. (2014) The relevance of checking population allele frequencies and Hardy-Weinberg Equilibrium in genetic association studies: the case of SLC6A4 5-HTTLPR polymorphism in a Chinese Han Irritable Bowel Syndrome association study. Immunol. Lett. 162, 276–278 10.1016/j.imlet.2014.08.009 [DOI] [PubMed] [Google Scholar]
  • 26.Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S.. et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31, 315–324 10.1002/art.1780310302 [DOI] [PubMed] [Google Scholar]
  • 27.Shao H.B., Ren K., Gao S.L., Zou J.G., Mi Y.Y., Zhang L.F.. et al. (2018) Human methionine synthase A2756G polymorphism increases susceptibility to prostate cancer. Aging 10, 1776–1788 10.18632/aging.101509 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Lindqvist E., Eberhardt K., Bendtzen K., Heinegard D. and Saxne T. (2005) Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann. Rheum. Dis. 64, 196–201 10.1136/ard.2003.019992 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Smolen J.S., Breedveld F.C., Schiff M.H., Kalden J.R., Emery P., Eberl G.. et al. (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 42, 244–257 10.1093/rheumatology/keg072 [DOI] [PubMed] [Google Scholar]
  • 30.Bowes J. and Barton A. (2008) Recent advances in the genetics of RA susceptibility. Rheumatology 47, 399–402 10.1093/rheumatology/ken005 [DOI] [PubMed] [Google Scholar]
  • 31.Cai X., Lu S., Zhang Z., Gonzalez C.M., Damania B. and Cullen B.R. (2005) Kaposi’s sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells. Proc. Natl. Acad. Sci. U.S.A. 102, 5570–5575 10.1073/pnas.0408192102 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Houbaviy H.B., Murray M.F. and Sharp P.A. (2003) Embryonic stem cell-specific microRNAs. Dev. Cell 5, 351–358 10.1016/S1534-5807(03)00227-2 [DOI] [PubMed] [Google Scholar]
  • 33.Davidson-Moncada J., Papavasiliou F.N. and Tam W. (2010) MicroRNAs of the immune system: roles in inflammation and cancer. Ann. N.Y. Acad. Sci. 1183, 183–194 10.1111/j.1749-6632.2009.05121.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Rodriguez-Rodriguez L., Castaneda S., Vazquez-Rodriguez T.R., Morado I.C., Gomez-Vaquero C., Mari-Alfonso B.. et al. (2011) Role of the rs6822844 gene polymorphism at the IL2-IL21 region in biopsy-proven giant cell arteritis. Clin. Exp. Rheumatol. 29, S12–S16 [PubMed] [Google Scholar]
  • 35.Tan Y., Qi Q., Lu C., Niu X., Bai Y., Jiang C.. et al. (2017) Cytokine imbalance as a common mechanism in both psoriasis and rheumatoid arthritis. Mediators Inflamm. 2017, 2405291. 10.1155/2017/2405291 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.van Steenbergen H.W., van Nies J.A., Ruyssen-Witrand A., Huizinga T.W., Cantagrel A., Berenbaum F.. et al. (2015) IL2RA is associated with persistence of rheumatoid arthritis. Arthritis Res. Ther. 17, 244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Li X., Chai W., Ni M., Xu M., Lian Z., Shi L.. et al. (2014) The effects of gene polymorphisms in interleukin-4 and interleukin-6 on the susceptibility of rheumatoid arthritis in a Chinese population. Biomed Res. Int. 2014, 265435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.O’Doherty C., Alloza I., Rooney M. and Vandenbroeck K. (2009) IL7RA polymorphisms and chronic inflammatory arthropathies. Tissue Antigens 74, 429–431 10.1111/j.1399-0039.2009.01342.x [DOI] [PubMed] [Google Scholar]
  • 39.Gomes da Silva I.I.F., Angelo H.D., Rushansky E., Mariano M.H., Maia M.M.D. and de Souza P.R.E. (2017) Interleukin (IL)-23 receptor, IL-17A and IL-17F gene polymorphisms in Brazilian patients with rheumatoid arthritis. Arch. Immunol. Ther. Exp. (Warsz) 65, 537–543 10.1007/s00005-017-0473-7 [DOI] [PubMed] [Google Scholar]
  • 40.Paradowska-Gorycka A., Sowinska A., Stypinska B., Haladyj E., Pawlik A., Romanowska-Prochnicka K.. et al. (2017) IL-12B gene polymorphisms and IL-12 p70 serum levels among patients with rheumatoid arthritis. Scand. J. Immunol. 85, 147–154 10.1111/sji.12514 [DOI] [PubMed] [Google Scholar]
  • 41.Do J.S., Fink P.J., Li L., Spolski R., Robinson J., Leonard W.J.. et al. (2010) Cutting edge: spontaneous development of IL-17-producing gamma delta T cells in the thymus occurs via a TGF-beta 1-dependent mechanism. J. Immunol. (Baltimore) 184, 1675–1679 10.4049/jimmunol.0903539 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Moser E.K., Sun J., Kim T.S. and Braciale T.J. (2015) IL-21R signaling suppresses IL-17+ gamma delta T cell responses and production of IL-17 related cytokines in the lung at steady state and after Influenza A virus infection. PLoS ONE 10, e0120169, 10.1371/journal.pone.0120169 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Huang Y., Matsumura Y., Hatano S., Noguchi N., Murakami T., Iwakura Y.. et al. (2016) IL-21 inhibits IL-17A-producing gammadelta T-cell response after infection with Bacillus Calmette-Guerin via induction of apoptosis. Innate Immunity 22, 588–597 10.1177/1753425916664125 [DOI] [PubMed] [Google Scholar]

Articles from Bioscience Reports are provided here courtesy of Portland Press Ltd

RESOURCES